Corporate
News release
TopTerumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO) hosted a successful collaboration customer event in South Korea.
‘Innovation through Collaboration’, was the theme of the customer event in Incheon, South Korea on 9th November 2022. With the focus on global market trends and solutions for parenteral drug delivery, Terumo shared unique solutions for the Ophthalmic, Aesthetic and Biotech segment, and an introduction of Terumo’s CDMO services for prefilled syringes and combination products. Over 70 participants joined the conference for an interactive and collaborative afternoon.
Terumo Pharmaceutical Solutions was represented by the local Terumo office in Korea along with Noritsugu Fujita, Executive Officer, Division President of Pharmaceutical Solutions Division and Marco Chiadó Piat, President of Terumo Pharmaceutical Solutions and Aiko Horiuchi, President, CDMO business, Pharmaceutical Solutions Division.
Noritsugu Fujita, Executive Officer, Division President of Pharmaceutical Solutions Division, said “It is fantastic to feel the energy here and the openness of our customers to partner with us and leverage our capabilities to find the best solutions for patients together”.
“South Korea is a very important region for us and with many pharma and biopharma companies working on biosimilars and innovative drugs. The global demand for high quality and reliable drug delivery solutions and CDMO services for injectable drugs is increasing. Terumo with a unique integrated model and track record can offer customers a simple supply chain, reduce risk and time to market” said Marco Chiadó Piat, President of Terumo Pharmaceutical Solutions.
“A very positive customer event and the start of a collaborative future together in this region for parenteral drug delivery solutions and CDMO business”, added Aiko Horiuchi, President, CDMO business, Pharmaceutical Solutions Division.
Terumo Pharmaceutical Solutions has recently launched new solutions for the Ophthalmic, Aesthetic, Biotech, and CDMO business to the global market which has generated a lot of interest in South Korea with our valued customers.
About Terumo Pharmaceutical Solutions
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, primary packaging solutions, and CDMO services. Terumo Pharmaceutical Solutions has decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to the latest stages of product commercialization to optimize critical aspects of parenteral drug delivery. Our comprehensive parenteral delivery product portfolio of injection, infusion, primary packaging solutions offers innovative drug delivery technologies ready for today’s most demanding applications.
www.terumopharmaceuticalsolutions.com
www.terumopharmaceuticalsolutions.com
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.